Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 22;10(8):ofad390. doi: 10.1093/ofid/ofad390

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — One-way sensitivity analyses for strategies that use long-acting cabotegravir-rilpivirine with wraparound services (CAB-RPV/WS) compared with integrase inhibitor–based antiretroviral therapy (ART) without wraparound services (INSTI) or INSTI-based ART with wraparound services (INSTI/WS) for the outcome of change in 3-year viral suppression (A) and life expectancy (B). The tornado diagrams in each panel display the impact of varying individual parameters on the change in 3-year viral suppression (A) and life expectancy (B) comparing CAB-RPV/WS with INSTI (top) and INSTI/WS (bottom). Each horizontal bar displays the range of outcomes that result from varying a single parameter. The base case value is in parentheses, followed by the range varied; the left-hand value would result in a decrease in the benefit of CAB-RPV/WS, and the right-hand value would result in an increase in the benefit of CAB-RPV/WS compared with INSTI (top) or INSTI/WS (bottom). A longer bar reflects a greater change in outcome as the parameter was varied. The thin vertical lines mark the outcomes from base case estimates: 3-year viral suppression (A, top: 28 percentage points gain with CAB-RPV/WS compared with INSTI; bottom: 7 percentage points gain with CAB-RPV/WS compared with INSTI/WS) and life expectancy (B, top: 2.0 years of life gained [YLG] with CAB-RPV/WS compared with INSTI; bottom: 0.4 YLG with CAB-RPV/WS compared with INSTI/WS). The thick vertical lines show where outcomes would be the same with the strategies. The bars that extend to the right of thick vertical lines (A, blue; B, green) show where CAB/RPV/WS would result in improved outcomes; bars that extend to the left of thick vertical lines (A, pink; B, yellow) show where INSTI (top) or INSTI/WS (bottom) would be preferred. Abbreviations: CAB-RPV/WS, long-acting injectable cabotegravir-rilpivirine with wraparound services; HIV, human immunodeficiency virus; INSTI, oral integrase inhibitor–based antiretroviral therapy; INSTI/WS, oral integrase inhibitor–based antiretroviral therapy with wraparound services; LTFU, loss to follow-up; PI, oral protease inhibitor–based antiretroviral therapy; PY, person-years; RMR, relative mortality ratio.